Featured
Environmental statement 2024 / EU-EMA 2026

Environmental statement 2024 / EU-EMA 2026
ID 25772 | 17.03.2026 / Attached
Reporting on performance for 1 January to 31 December 2024: in accordance with EMAS Regulation Article 4 (1) (d) and Annex IVs
This environmental statement has been developed to provide information to the public and other interested parties about the European Medicines Agency’s (the ‘Agency’) environmental performance and initiatives in 2024.
It is prepared in accordance with the European Eco Management and Audit Scheme (EMAS) standard, revised Regulation (EC) No 1221/2009 included Annexes I, II, III as amended in 2017 to reflect the revised ISO 14001:2015, and Annex IV, as amended in 2018 to reflect the environmental reporting requirements, whereby it also fulfils the requirement of disclosure of information relating to environmental matters in accordance with Directive 2014/95/EU.
Furthermore, the Agency is voluntary using the JRC Science for Policy Report ‘Best Environmental Management Practice for the Public Administration Sector’2 (BEMP) for the preparation of this Environmental Statement, specifically chapter 2 and 12, since that is the Management Practice closest to our activities.
Additionally, the Agency is also voluntarily using the European Commission Decision (EU) 2019/61 on the sectoral reference document on best environmental management practices, sector environmental performance indicators and benchmarks of excellence for the public administration sector under the EMAS regulation (SRD), with special focus on chapter 3.1 ‘Best Environmental Management Practices for sustainable offices’ and chapter 3.11 ‘Best environmental management practices’ for green public procurement taken into account, when applicable, for the same reasons.
...
European Medicines Agency, 2026
Collegati
Allegati
|
Descrizione |
Lingua |
Dimensioni |
Downloads |
|
|
EN |
1341 kB |
3 |